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Abstract
The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the
skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracuta-
neous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on char-
acteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for
differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases
are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of
localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with dis-
eases of the rheumatological spectrum.
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Localized scleroderma (LS) comprises a spectrum of sclerotic
diseases that primarily affect the skin. Depending on the respec-
tive subtype (Table 1), LS can also involve adjacent tissues such
as the fat, fascia, muscle and bone, but not internal organs.1 The
incidence of LS ranges from 0.4 to 2.7 per 100 000 people.2,3
The disease occurs 2.6–6 times more frequently in women than
men.4 Morphea the most frequent subtype of LS usually appears
in adults between 40 and 50 years of age, whereas linear subtypes
primarily present in childhood between 2 and 14 years of age.5
Other, rarer subtypes of LS have a peak incidence in the third
and fourth decade of life.
Little is known about the potential triggers of the disease. It
has been hypothesized that certain stimuli, e.g. infections (par-
ticularly borrelia), trauma, radiation or drugs (bleomycin, vita-
min K1 and L-5-hydroxytryptophan plus carbidopa, balicatib)
might cause microvascular injuries and induce T-cell activation
that subsequently result in a release of various adhesion mole-
cules.5 Upregulation of some of these adhesion molecules (e.g.
vascular cell adhesion molecule-1 and intercellular adhesion
molecule-1) might induce T-cell activation. This, in turn, acti-
vates the release of key pro-fibrotic mediators, such as trans-
forming growth factor-beta (TGF-beta), platelet-derived growth
factor, connective tissues growth factor, interleukin (IL)-4, IL-6
and IL-8, and certain chemokines.6–11 Ultimately, and similarly
to systemic sclerosis (SSc), activation of these pro-inflammatory
and pro-fibrotic signals leads to excessive collagen production
and decrease of matrix metalloproteinases responsible for colla-
gen degradation.12 However, transition from LS to SSc does not
occur. Moreover, several reports of familiar clustering and coex-
istence of LS with autoimmune diseases (e.g. Hashimoto
thyreoiditis, alopecia areata, vitiligo, type-1 diabetes) and genital
lichen sclerosus suggest a possible genetic component.13,14
Diagnostic procedures
Clinical presentation and physical examination A German
group of experts proposed a classification of LS that considers the
extent and depth of fibrosis and comprises five main types and
certain subtypes (Table 1). The authors consider eosinophilic
fasciitis as a separate type within the spectrum of LS. The clinical
presentations of each type or subtype are summarized in Table 1.
Clinical scores In 2009, the first validated skin score for LS
called ‘modified localized scleroderma skin severity index’
(mLoSSI) was introduced. This score evaluates erythema, skin
thickness and development of new skin lesions or lesional exten-
sion in 18 anatomical regions and has demonstrated a high
inter-rater agreement.18 The same group of researchers later
introduced a score for skin damage in LS, called ‘localized scle-
roderma skin damage index’ (LoSDI).19 Consequently, it was
recommended to combine the LoSSI, LoSDI and the Physician’s
Global Assessment to measure both activity and damage in LS.
These together compose the ‘localized scleroderma cutaneous
© 2017 European Academy of Dermatology and VenereologyJEADV 2017, 31, 1401–1424
EDF S1-guideline on sclerosing skin diseases, Part 1 1403
assessment tool’ (LoSCAT) that could become a standard tool to
evaluate skin affection in LS. Patients’ quality of live can be eval-
uated with the Dermatology Life Quality Index or the Hospital
Anxiety and Depression Scale.
Histopathology Physicians should take care that the biopsy
excision is sufficiently deep as some LS subtypes may primarily
involve the subcutis or underlying fascia and muscle. By
histopathology, it is neither possible to distinguish between LS
and SSc nor to differentiate among different LS subtypes. Early
inflammatory skin lesions of LS are characterized by thickened
collagen bundles within the reticular dermis that run parallel to
the skin surface, and by the presence of dense inflammatory
infiltrates between the collagen bundles and around blood ves-
sels and sweat glands. Lymphocytes predominate the inflamma-
tory infiltrates, but plasma cells, histiocytes and eosinophilic
Table 1 Classification according to the German guideline by Kreuter et al.1 and clinical presentation of localized scleroderma/morphea.
All types may present with overlapping features of other types (e.g. generalized types with linear or deep aspects)




• Oval-shaped lesions surrounded by an erythematous border (‘lilac ring’)
• In later stages, sclerotic in the centre with a whitish or ivory colour; old lesions may become
atrophic and dyspigmented
• May lead to hair loss and loss of the skin appendages
• Predominantly located on the trunk
Guttate morphea • Multiple yellowish or whitish, small sclerotic lesions with a shiny surface
• Early inflammatory lesions may simply present as erythematous maculae
• Predominantly located on the trunk
Atrophoderma idiopathica of
Pierini and Pasini (superficial
morphea)
• Symmetrical, single or multiple, sharply demarcated, hyperpigmented, non-indurated
patches
• Located on the trunk or extremities
Generalized type
Generalized LS/morphea • Four or more indurated plaques of more than 3 cm in diameter, involving two or more of
seven anatomical sites (head-neck, each extremity, anterior trunk and posterior trunk)15
• Often distributed symmetrically and tend to coalesce
Disabling pansclerotic
morphea
• Extensive involvement of the skin, fat tissue, fascia, muscle and bone
• Fibrosis often results in severe contractures and poorly healing, large ulcerations and
necroses
Linear type
Linear LS/morphea of the
extremities
• Longitudinally arranged linear, band-like lesions that may follow the lines of Blaschko16
• May heal with residual hyperpigmentation or
• May cause severe growth retardation, muscle atrophy, flexion contractures, myositis,
arthritis and psychological disability
Linear LS/morphea ‘en coup
de sabre’
• Typically located on the frontoparietal region, ranging paramedian from the eyebrows into
the hair-bearing scalp




• Progressive facial hemiatrophy with involvement of the subcutaneous tissue, muscle and
bone, but usually not the skin
• May result in severe facial asymmetry
• Coincidence with linear LS ‘en coup de sabre’ in up to 40%17
Deep type (deep morphea) • Fibrotic process mainly affecting the deeper layers (subcutaneous fat tissue, fascia and
underlying muscle)
• Typically arranged symmetrically on the extremities
Mixed type
• Combined linear and plaque type, or linear and generalized LS; predominant in children.
Eosinophilic fasciitis (Shulman
syndrome)
• Rapid onset with symmetrical swelling of the skin
• In later stages, indurated and fibrotic lesions with typical ‘peau d‘orange’ like appearance
• Cutaneous veins might appear as depressed compared to the surrounding tissue (‘negative
vein sign’)
• Predominantly located on the extremities
LS, localized scleroderma.
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granulocytes might be present as well. The overlying epidermis
might be either unaffected or thin and atrophic. In the late fibro-
tic stage, the lesional skin becomes relatively avascular, and often
there is only little evidence of ongoing inflammation. Late
lesions usually contain collagen fibres that are tightly packed and
highly eosinophilic. Sweat glands are atrophic or absent. Colla-
gen may replace fat cells in the subcutaneous tissue.1,20
Laboratory parameters Routine laboratory parameters should
include blood differential and clinical serum chemistry including
lactate dehydrogenase, creatine kinase (especially in case of sus-
pected concomitant myositis), blood sedimentation rate and C-
reactive protein. Abnormal blood findings are frequent in juve-
nile LS. In the active stage of generalized LS, blood eosinophilia
may be observed.21 In patients with linear LS of the extremities
with concomitant joint involvement, increased levels of rheuma-
toid factor may be present, and do sometimes correlate with the
clinical degree of arthritis activity.22 Although certain autoanti-
bodies (e.g. antinuclear, anti-single strand DNS, anti-histone,
anti-topoisomerase II alpha, anti-small nuclear ribonucleopro-
tein and anti-matrix metalloproteinase antibodies) have been
described in patients with LS,23–28 routine screening for these
antibodies is not recommended. Additional diagnostics (e.g.
screening for antibodies against extractable nuclear antigens)
should be only performed to confirm or exclude SSc. Likewise,
blood screening for Borrelia burgdorferi is not generally recom-
mended and should only be performed in clinically suspicious
cases.
Imaging Patients with LS ‘en coup de sabre’ and/or pro-
gressive facial hemiatrophy often suffer from neurological
symptoms (e.g. migraine, headaches and epilepsy).29–31 Thus,
cranial magnetic resonance imaging (MRI) should be consid-
ered to detect potential subcortical calcifications or brain
atrophy.23,32 On the other hand, many patients are asymp-
tomatic even if such abnormalities are seen. Ophthalmolo-
gists or oral surgeons should be consulted, as indicated.
MRI and computed tomography (CT) studies might likewise
be helpful for surgical planning (e.g. in LS ‘en coup de
sabre’ type) or to detect muscle, joint or bone involvement,
for instance in linear LS of the extremities.
Instrument-based outcome measures A variety of instrument-
based procedures have been reported in clinical trials on LS, e.g.
ultrasound scanning, cutometer, durometer, thermography,
laser doppler flowmetry and a computerized skin score. In most
of the studies, these procedures were used as secondary outcome
measures.
Differential diagnoses
A variety of differential diagnoses should be considered in LS.33
In daily routine, the physicians’ pivotal challenge is to
differentiate LS from SSc.5 Typical facial (e.g. telangiectases,
beak-shaped nose and microstomia) and vascular features (e.g.
Raynaud’s phenomenon, pitting scars and digital ulcers) of SSc
as well as highly specific serum antibodies (e.g. anti-centromere
antibodies and anti-Scl-70 antibodies) are absent in LS.20 All dif-
ferential diagnoses with respect to LS subtypes and stage of dis-
ease are summarized in Table 2.
Treatment
Although no causal treatment for LS exists, a variety of therapeu-
tic options is available, especially for the active phase of disease.
In general, treatment options for LS might be divided into topi-
cal and systemic therapy as well as ultraviolet (UV) photother-
apy. The extent and severity of LS should be taken into account
before initiating the respective therapy. For example, topical and
Table 2 Differential diagnoses of localized scleroderma/morphea
according to the German guideline for the diagnosis and treat-
ment1
LS subtype Differential diagnoses

















Limited LS (morphea) – late





Limited LS (morphea) – late
stage mainly with sclerosis
Necrobiosis lipoidica
Pretibial myxedema
Generalized LS Systemic sclerosis†














†The most relevant differential diagnoses.
‡Also known as nephrogenic fibrosing dermopathy.
§For example, lipodystrophia centrifugalis abdominalis infantilis.
LS, localized scleroderma.
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UV phototherapy are usually appropriate in limited types of LS
that are restricted to the skin, whereas generalized, linear or deep
types usually require systemic treatment. To prevent persistent
damage from linear types of juvenile LS, effective systemic ther-
apy should be initiated in the active stage as early as possible.
Hereafter, all treatment options that have been reported for LS
are summarized. A treatment algorithm that incorporates the
subtype, severity and extent of LS is provided in Fig. 1. When
evaluating the treatment efficacy, it should be taken into account
that reduction of skin sclerosis starts 8–12 weeks after initiation
of therapy, at the earliest. None of the below mentioned thera-
pies are officially licensed in Europe for LS.
Topical therapy Topical corticosteroids are the mainstay of
topical treatment in LS, although no well-performed studies
exist. Therapy with moderate- to high-potent corticosteroids
should be performed in the active phase of disease, and their
application should be restricted to a total of 3 months. Longer
application of topical corticosteroids should be given as an inter-
val therapy. To increase the efficacy, an application under occlu-
sion might be considered. Intralesional steroid therapy might be
performed in LS ‘en coup de sabre’, with injections into the
active margin.
Topical calcipotriol 0.005% should be considered for active
inflammatory superficial types of LS with a low degree of sclero-
sis. This treatment should be performed twice daily (under
occlusion) for a minimum of 3 months.34,35
Tacrolimus 0.1% ointment might be an effective treatment
option for active LS lesions. A recent double-blinded, placebo
(petroleum emollient)-controlled pilot study has shown that
topical tacrolimus significantly improves LS in terms of changes
in surface area, erythema and induration, as assessed by clinical
and durometer scores.36 So far, studies on pimecrolimus for LS
are missing.
Localized scleroderma
Subtype with limited skin involvement 
(reaching to the dermis)
Subtype with severe skin and/or musculoskeletal 
involvement (affecting fat tissue, fascia, muscle, joints, 
and bones, or widespread skin involvement)
Consider risks and benefist of the treatment
To increase the 
effects, occlusive 
application may be 
considered
Systemic glucocorticoids:
IV: 500–1000 mg 
methylprednisolone/day on 
three consecutive days per 
month, for up to 3–6 months
or
oral: 0.5–2 mg prednisolone/
kg bodyweight/day for 2–4 
weeks, tapering of dosage 
thereafter
Systemic glucocorticoids:
IV: 30 mg methylprednisolone/kg 
bodyweight/day (max. 1000 mg/day) on 
three consecutive days per month, for at 
least 3–6 months
or
oral: 0.5–2 mg prednisolone/kg bodyweight/
day (max. 60 mg/day), preferably divided 
into 2–3 daily doses, for 2–4 weeks, 
tapering of dosage thereafter 
Alternatively:
Topical calcipotriol (alone 
or combined) or topical 
calcineurin inhibitor, 1-2 
times daily
Topical glucocorticoids:
High potent (e.g., globetasol) 
once daily for up to one month
or
mid-potent (e.g., mometasone 
furoate) once daily for up to 
three months
Any longer therapy with 
topical glucocorticoids 






 15 mg/m2 BSA/week, 
maximally 25 mg/week
Duration of therapy should 
be at least 12 months, 
depending on the efficacy, 
tapering of dosage should 
be considered
PUVA therapy:
Oral, bath, or cream, 
depending on the extent 
of disease, 2–4 times per 
week, minimum of 30 UV 
irradiations
UVA1 phototherapy:
50–80 J/cm2, 3–5 mes 
per week, minimum of 30 
UV irradiaons
and/or and/or
Figure 1 Treatment algorithm for localized scleroderma depending on the clinical subtype and extent of disease. BSA, body surface
area; IV, intravenous; PUVA, psoralen plus ultraviolet A irradiation.
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The topical immune response modifier imiquimod has been
reported to significantly improve abnormal pigmentation, scle-
rosis and erythema in LS37–39 but cannot be recommended for
LS until more valid data are available. Intralesional interferon
gamma did not prove effective in LS in a double-blinded, pla-
cebo-controlled trial.40
Systemic therapy Systemic corticosteroids. Systemic corticos-
teroids are widely used agents in LS, particularly in linear,
generalized and deep subtypes. In the only published uncon-
trolled study on 17 patients with LS where a dosage of 0.5–
1.0 mg prednisone equivalent per kg bodyweight and day
was used, a marked improvement was noticed in nearly all
of the patients.41 However, about one-third of patients expe-
rienced recurrences after finishing therapy. Systemic corticos-
teroids are safe and effective in active lesions of LS and
should be considered in patients with severe disease, espe-
cially in those forms affecting extracutaneous structures (e.g.
fat tissue, fascia, muscle and bone). Moreover, systemic cor-
ticosteroids are the first-line treatment option in eosinophilic
fasciitis.42 When planning the treatment, one should keep in
mind that clinical effects are sometimes seen 3 months after
onset at the earliest.
Methotrexate. Methotrexate is a well-known immunosuppres-
sive agent that has been used in adults and children with
well-documented side-effects. Among systemic treatments for
LS, best evidence exists for the use of methotrexate. In a
placebo-controlled study, 70 children with active LS were
randomized to receive methotrexate orally (15 mg/m2, maxi-
mum: 20 mg; n = 46) or placebo (n = 24). Oral prednisone
(1 mg/kg/day, maximum: 50 mg) was added in both arms
for 3 months. In both arms, a reduction of the computer-
ized clinical scores was observed within the first 6 months.
However, at month 12, a significant decrease of the clinical
score as well as target lesion temperature in infrared ther-
mography was only observed in the methotrexate group.43
In three non-controlled prospective studies (24 adults and
10 children in total), a combination of high-dosage intra-
venous methylprednisolone and methotrexate (adults: 15 mg/
week; children: 0.3 mg/kg/week) was used. All adults and
nine of the ten children experienced a significant improve-
ment under therapy, as assessed by a (non-validated) clinical
score and ultrasound scanning.44–46 Likewise, in four retro-
spective studies (52 patients with methotrexate monotherapy
and 67 patients with a combination of methotrexate and
systemic corticosteroids), a clinical improvement was
observed in 97% of patients.47–50 However, 28% of patients
with juvenile LS experienced a relapse after treatment with
methotrexate.51 In 2012, the ‘Childhood Arthritis and
Rheumatology Research Alliance’ (CARRA) recommended
three different treatment regimens for juvenile LS: (i)
methotrexate monotherapy, (ii) pulsed methotrexate and
methylprednisolone given intravenously and (iii) pulsed
methotrexate and prednisone given orally.52 These recom-
mendations have been incorporated in the treatment algo-
rithm of this guideline (Fig. 1).
Mycophenolate mofetil. In vitro studies have shown that
mycophenolate mofetil (MMF) inhibits the proliferation of
lymphocytes, but also of other mesenchymal cell types,
including smooth muscle cells and fibroblasts.53 In 2009, a
case series of seven methotrexate-resistant LS patients treated
with MMF has shown improvement of skin sclerosis and
inflammation, as documented with infrared thermography
and clinical scoring.54 Consequently, MMF should be consid-
ered as a second-line therapy if methotrexate has failed.52
Miscellaneous. Numerous other systemics have been reported in
cases of LS, including cyclosporine A, azathioprine, chloroquine
and hydroxychloroquine, phenytoin, colchicine, retinoids, intra-
venous immunoglobulins (IVIg), abatacept, infliximab, ritux-
imab or imatinib.55–59 These treatments should be reserved to
single severe cases with contraindications or failure to standard
therapy.
Agents currently not recommended for the treatment of LS. Oral
calcitriol failed to achieve any significant improvement in
comparison with placebo.60 D-penicillamine has been
reported as effective in small case series of LS patients,61,62
but cannot be recommended because of the low evidence
level and the problematic safety profile. Penicillin has long
been used for the treatment of LS because the disease can
manifest after an infection with borrelia. However, direct
anti-fibrotic effects have so far not been demonstrated.
UV phototherapy Within the last two decades, the vast
majority of clinical studies on LS came from the field of pho-
todermatology.63 One of the rationales for using UV pho-
totherapy in sclerotic skin diseases is the fact that UV can
induce interstitial matrix metalloproteinases and thus exerts
anti-fibrotic and anti-inflammatory effects.64–66 In addition,
UV phototherapy leads to apoptosis of dermal T cells, deple-
tion of Langerhans cells and modulation of several pro-
inflammatory cytokines.63 As longer wavelengths in the UVA
range (320–400 nm) penetrate deeper into the dermis than
does UVB (280–320 nm), most studies have focused on UVA.
However, as the penetration is not deep enough to affect lay-
ers beyond dermis such as fat tissue, fascia, muscle and bone,
UV phototherapy may not be effective in LS subtypes with
involvement of these deep structures. The dosages and dura-
tion of UVA irradiation used in the treatment of sclerotic
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skin diseases are most likely too low to induce any significant
skin damage or skin cancer.67
PUVA phototherapy. To avoid the well-known side-effects of
oral application of 8-methoxypsoralen, PUVA in LS was
mainly applied as bath-PUVA phototherapy. In a retro-
spective study published in 2013, 28 patients were treated
with three-times-weekly bath-PUVA and experienced com-
plete clearance of all lesions in 39%, clinical improvement
in 50% and no response in 10% of patients.68 Similar
encouraging results were reported from four patients trea-
ted with cream-PUVA phototherapy.69 PUVA phototherapy
is usually performed 2–3 times weekly for a total of 30
irradiations.
Broadband UVA. Three prospective studies have been published
on the use of broadband UVA (320–400 nm) in LS.70–72 Among
these, the largest study included 63 patients.72 The three dosages
used (5, 10 and 20 J/cm² for 20 irradiations each) were similar
in efficacy. Controlled studies comparing broadband UVA with
other UV modalities are lacking.
UVA1 phototherapy. In the area of phototherapy, the most
robust data exist for UVA1. Three different dosages of
UVA1 can be distinguished: low-dose UVA1 (10–29 J/cm²),
medium-dose UVA1 (30–59 J/cm²) and high-dose UVA1
(60–130 J/cm²). All regimens have been used in LS, and the
first report was published in 1991.73 The first prospective
study on UVA1 phototherapy in LS demonstrated that
high-dose UVA1 is highly effective, but low-dose UVA1
failed to show any substantial effects in LS.74 By contrast,
several prospective studies performed some years later
showed that low- and medium-dose UVA1 are effective as
well.34,75–81 So far, only one randomized controlled study
compared low- and medium-dose UVA1, and narrow-band
UVB phototherapy in a collective of 64 LS patients. All
three UV regimens significantly improved the skin scores,
with medium-dose UVA1 being significantly better than
narrow-band UVB.82 Whether patients with darker skin
respond less to UVA1 phototherapy is still a matter of
debate.83,84 Moreover, it has been shown that within 3 years
after therapy, about 50% of patients treated with UVA1
experience recurrences.85 In these cases, a second cycle of
UVA1 phototherapy should be considered. UVA1 is usually
performed 3–5 times weekly for a minimum of 30 irradia-
tions. Success with extracorporeal photopheresis has also
been described in case reports.86–89
Physiotherapy Studies on physiotherapy in LS are lacking.
Nevertheless, physiotherapy is an important component in the
multimodal treatment concept for LS, especially for linear, gen-
eralized, deep and mixed types of LS. It should not be per-
formed in the active, inflammatory stage of disease. Massage
and lymphatic drainage can be added to systemic therapy in
patients with sclerotic stage. In clinical practice, physiotherapy
is usually performed once or twice a week for at least
3 months.
Surgical therapy Surgical therapy is predominantly indi-
cated in linear types of LS. In linear LS of the limbs, epi-
physiodesis of the healthy extremity to adjust leg length
inequality can be considered in consultation with an expe-
rienced paediatric orthopaedist. Plastic-surgical interventions
might be considered for cosmetic reasons in linear LS ‘en
coup de sabre’ or progressive facial hemiatrophy. It is
important that surgical interventions are only considered in
the inactive stage of disease to keep down the risk for
reactivations.
Clinical course and prognosis
So far, only limited data are available on the long-term
clinical course of LS. A recent retrospective analysis includ-
ing 344 patients with adult or juvenile LS from the Nether-
lands demonstrated that about one quarter of the patients
experienced a reactivation of disease. Univariate analysis
demonstrated that the age at onset of disease was a risk
factor for recurrent disease; relapses occurred significantly
more often in paediatric (27%) compared to adult (17%)
LS patients. Moreover, disease subtype was another risk
factor; 37% of patients with linear LS of the limbs (either
solitary or as part of mixed type of LS) experienced a
relapse, whereas recurrences in the other subtypes occurred
less frequently (17%). The two most frequent subtypes in
adults (morphea/plaque type and generalized LS) had recur-
rence rates of 16% and 25%, respectively. Importantly, this
study also showed that disease relapses can occur after
years of quiescent disease; the median time between disease
remission and first recurrence was 26 months in juvenile
and 27 months in adult LS, respectively.90 In the study of
Saxton-Daniels et al. regarding long-term outcome of paedi-
atric cases, 89% of the paediatric onset cases developed
new or expanded lesion over time. Time to recurrence of
activity ranged from 6 to 18 years from initial disease
onset.91 The clinical course of disease is often more severe
in juvenile linear LS as compared to adult linear LS. It
may lead to considerable atrophy of the skin, fat tissue,
fascia and muscle resulting in functional, physical and
mental disability. Moreover, 30–50% of patients with linear
LS experience osteoarticular complications on the affected
extremity.92–94
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Recommendations
• Patients with LS should be evaluated for possible concurrent rheumatic and autoimmune diseases. To exclude concomitant
genital lichen sclerosus, an inspection of the anogenital region should be performed in patients with LS, especially in those
with limited or generalized types.
• Blood screening should be performed in patients with LS prior to systemic therapy. It should include blood differential and
serum chemistry. Routine screening for antinuclear antibodies (ANA) and borrelia is not recommended. Screening for anti-
bodies against extractable nuclear antigens should be only performed to confirm or exclude SSc (if clinically relevant).
• Among the clinical scores for LS, the most robust data exist for the validated LoSCAT. Photodocumentation of clinical
lesions is advisable.
• A biopsy should be considered in case of inconclusive clinical presentation. If deep, generalized or linear types of LS are sus-
pected, a deep biopsy should be performed that includes subcutaneous and fat tissue. If eosinophilic fasciitis is suspected,
deep biopsy must include the fascia as well.
• Ultrasound scanning, cutometer, durometer, thermography, laser doppler flowmetry or the computerized skin score can be
considered to evaluate disease activity and clinical course of LS over time.
• In patients with linear LS ‘en coup de sabre’ or progressive facial hemiatrophy, neurological examination and MRI of the
skull should be performed to exclude an affection of the brain. MRI and CT might be helpful for surgical planning and to
detect muscle or bone involvement.
• In juvenile LS affecting the head (LS ‘en coup de sabre’ or progressive facial hemiatrophy), and in linear LS affecting the
joints, screening for uveitis and arthritis should be performed.
• Routine systemic workup is not recommended in LS.
• Topical glucocorticosteroids can be used in the active stage of patients with limited types of LS (high-potent corticosteroids
for up to 4 weeks, mid-potent corticosteroids for up to 12 weeks). To increase the efficacy, an occlusive application can be
considered. Longer treatment should be performed as interval therapy. Alternatively, topical calcipotriol or topical cal-
cineurin inhibitors can be used. If the lesions do not adequately respond to topical- or phototherapy, systemic therapy
should be considered.
• Methotrexate is the current first-line treatment for subtypes of LS with severe skin affection or musculoskeletal involvement.
Duration of methotrexate therapy should be at least 12 months, and a reduction of dosage can be considered after first signs
of clinical improvement.
• In the active stage of disease, concomitant treatment with systemic corticosteroids should be performed if contraindications
are absent, especially in severe cases (linear or deep LS) or in cases with extracutaneous involvement. Alternatively, MMF
should be considered in cases with failure or contraindications to methotrexate.
• First choice phototherapy for limited types of LS is medium-dose UVA1. Alternatively, bath-PUVA or cream-PUVA pho-
totherapy can be considered.
• Physiotherapy and manual therapy should be added to topical and systemic therapy in all types of LS that result in restric-
tions of motion. Massage and lymphatic drainage should be concomitantly performed in sclerotic types of LS.
• Functionally indicated surgical interventions should be performed in the inactive stage of disease and concern patients with
linear LS. Plastic-surgical procedures can be considered for linear LS ‘en coup de sabre’ and progressive facial hemiatrophy.
• Clinical follow-up visits (at least once a year) should be performed in LS with high risk for recurrences after successful treat-
ment. Children, especially those with linear or mixed types of LS, are particularly affected by recurrent disease. In these




SSc is a heterogeneous, chronic autoimmune disorder leading to
fibrosis of the skin and many internal organs.95 Its incidence is
0.3–2.8 per 100 000 per year with female predominance (3 : 1).
A positive family history increases the relative risk by 12-fold
compared to the population without genetic predisposition. Cel-
lular and humoral immune reactions (cytokines, adhesion mole-
cules, growth factors) are centrally involved in the pathogenesis
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of SSc. Apart from autoimmunity, various infections such as
cytomegalovirus, parvovirus B19, human papilloma virus and
toxoplasmosis as well as environmental toxins have been impli-
cated as causes of SSc.96
Diagnostic procedures
Clinical presentation and physical examination The diagnosis
of SSc/systemic scleroderma is challenging due to the hetero-
geneity of disease manifestations and disease course. In 1980,
the American College of Rheumatology (ACR) published pre-
liminary criteria for the classification of patients with estab-
lished disease.97 A subclassification, developed by LeRoy
et al.,98 has been the most widely used classification system in
clinical practice and forms the basis for many registries
worldwide (Table 3).99–101
It has been widely accepted that the so called ‘CREST syn-
drome’ and ‘systemic sclerosis sine scleroderma’ can be seen
as a part of the disease spectrum of the limited cutaneous
form of SSc.102 For patients with very early disease (also
referred to as very early/early SSc, pre-SSc or undifferentiated
connective tissue disease), there are no generally accepted
diagnostic criteria.103 Among these cases, only two-thirds of
those patients who present with Raynaud’s phenomenon, nail
fold capillaroscopic changes and/or SSc-specific antibodies
(anti-centromere, anti-topoisomerase-1) will develop definite
SSc after 5 years, and almost 80% develop SSc in the long
term. In contrast, those who have neither scleroderma pattern
on capillaroscopy nor SSc-specific antibodies in serum mostly
do not develop SSc (1.8% during long-term follow-up).104
Skin manifestations. Raynaud’s phenomenon is present in more
than 90% of patients. It typically affects the hands, less com-
monly the feet, but may also involve the tongue, ears and nose.
Cold exposure is the usual trigger, but emotional stress may
evoke the same symptoms.105 At the onset of the disease, partic-
ularly in the diffuse form, patients tend to have swollen fingers
and hands over extended time periods (so called ‘puffy hands’).
Sclerotic changes follow later on, finally leading to dermatogenic
contractures and sclerodactyly, perioral plication and microsto-
mia and mask-like facial stiffness. They are possibly accompa-
nied by additional symptoms such as hair loss, diminished
sweating, hyperpigmentation, depigmentation or severe pruri-
tus. In later disease stages, internal organ involvement may pro-
gress, while skin fibrosis of the trunk and proximal extremities
will diminish. Among patients with SSc, 15–25% have active dig-
ital ulcerations, and 35% have digital ulcerations or had them in
the past, although this number varies considerably between cen-
tres and studies.106–109 Ulcers that occur on the fingertip are
thought to be exclusively due to ischaemia, whereas ulcers over
the extensor surfaces of the proximal and distal interphalangeal
joints are usually due to a combination of poor perfusion,
stretched fibrotic skin and trauma. Digital ulcers may be compli-
cated by secondary infection, osteomyelitis, acro-osteolysis or
gangrene.110 Calcinosis cutis is marked by subcutaneous calcium
carbonate deposits, which appear in all subtypes of SSc and most
frequently on the acral parts of the body. They may induce
superficial erosions and cause intense pain for the patient.
Musculoskeletal disorder. Arthralgia and musculoskeletal pain
are among the most frequent complaints in SSc and may lead to
secondary fibromyalgia.111 Tendon friction rubs are a typical
sign of an inflammatory, progressive form of the disease. Muscle
weakness and a varying increase in serum creatine kinase levels
are quite common and can indicate the presence of an SSc-myo-
sitis overlap syndrome. Inflammatory arthritis can occur in up
to 10% of patients and raises the suspicion of the presence of an
SSc-rheumatoid arthritis overlap syndrome.
Pulmonary manifestations. Interstitial lung disease affects up to
65% of SSc patients to varying degrees. The typical presentation is
a predominantly bibasilar pattern which most often corresponds
to a non-specific interstitial pneumonitis.112 The sensitivity of
high-resolution CT is superior when compared with lung func-
tion testing.113 Lung function testing should include spirometry,
body plethysmography and the diffusing capacity of lung for car-
bon monoxide (DLCO; corrected for haemoglobin). Pulmonary
arterial hypertension occurs in about 15% of patients and
Table 3 Subclassification of systemic sclerosis according to LeRoy et al. (1988)98
Limited form Diffuse form
• Acral sclerosis
• Skin involvement of the extremities distal to
the elbow and knee joints
• Possible involvement of the face
• Long duration of Raynaud’s phenomenon
• Late pulmonary arterial hypertension
• Often anti-centromere positive
• Progressive systemic sclerosis
• Rapid involvement of the trunk, face and
extremities
• Lung fibrosis
• Early onset of Raynaud’s phenomenon (within
1 year of skin changes)
• Often anti-topoisomerase-1 positive
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develops particularly in patients with long disease duration and
anti-centromere antibodies in serum. All SSc patients should be
evaluated for possible pulmonary arterial hypertension in line
with current recommendations and referred for specialist man-
agement. Annual screening on symptoms (unexplained or pro-
gressive dyspnoea, syncope, signs of right-heart failure) and by
echocardiography are strongly recommended in all SSc patients.
Gastrointestinal manifestations. The gastrointestinal tract is fre-
quently involved, with 80% of patients having oesophageal
involvement and 40–70% having involvement of the stomach,
and small and large intestine.100,114 In long-standing disease
(>10 years), upper gastrointestinal involvement occurs in nearly
all patients and may include Barrett’s oesophagus as a late sequel
of reflux disease, and telangiectasia on the mucosa as a potential
source of occult intestinal bleeding.115
Cardiovascular manifestations. The nature and severity of car-
diac disease depends on the extent of myocardial fibrosis, and
on the extent to which concurrent fibrosis of the lung, and thick-
ening and fibrosis of the small pulmonary arteries place an addi-
tional burden on the circulation. Myocarditis and pericarditis
can be observed in a subset of patients. These may lead to diag-
nostic uncertainty.116
Renal disorder. Chronic renal involvement in SSc is associated
with a slowly progressive obliterative vasculopathy. Acute renal
crisis is a serious and potentially fatal SSc complication. It occurs
most likely in patients with the progressive diffuse form with a
disease duration of <4 years. The presence of anti-RNA poly-
merase III antibodies is considered a particular risk factor and is
detected in about one-third of cases.117
In 2013, the ACR and the European League Against Rheumatism
(EULAR) published new diagnosis criteria (Table 4). However,
they were primarily developed for clinical research purposes. More-
over, they cannot be applied to patients without skin involvement
of the hands or to patients with scleroderma-like disorders.118
Capillaroscopy Capillaroscopy (e.g. by use of nail fold video-
capillaroscope, stereomicroscope or dermatoscope) is a well-
established, non-invasive technique for the identification of
changes in the nail fold capillaries that differentiate primary Ray-
naud’s phenomenon from SSc.119
Clinical score The best and validated tool to measure the pro-
gress of the skin sclerosis is the modified Rodnan skin score
(mRSS). The mRSS is evaluated by manual palpation at 17 dif-
ferent anatomical areas. The skin score is 0, 1, 2 and 3 for unin-
volved skin, mild thickening, moderate thickening and severe
thickening, respectively. Subsequently, the sum over all anatomi-
cal areas will be used as the total skin score. The mRSS is feasible,
is reliable and has been validated for initial and follow-up skin
evaluation. The administration of this simple method requires
some experience, and a careful teaching process is warranted.120
Laboratory parameters Autoantibodies targeting characteristic
nuclear antigens are one of the hallmarks of SSc. The frequency
of detection of ANA in SSc patients in a recent study approached
95%,101 which corresponds well with ANA frequencies of
between 85% and 99% reported in other literature. In this study,
86.6% of the ANA-positive patients had antibodies specific for
SSc, 96.4% of which were detecting five antigens [i.e. cen-
tromere, topoisomerase-1, RNA polymerase III, exosomal
ribonuclear protein (PM/Scl) and uridine-rich small nuclear
ribonuclear protein (U1-snRNP)] (Table 5). It is generally well
accepted that the SSc-specific antibodies described in Table 5
are largely mutually exclusive. Coincidences in individual
patients do occur but are rare.
Organ-oriented diagnostic workup As a baseline assessment, a
broad range of clinical, laboratory and radiographic examina-
tions is indicated to explore the patients’ general and organ sta-
tus thoroughly. The diagnostic procedures recommended are
summarized in Table 6. At least annual, lifelong follow-up of
patients is recommended due to the chronic nature of the dis-
ease. In patients with progressive disease, corresponding with
disease activity, patients should be followed more frequently.
Table 4 American College of Rheumatology/European League
against Rheumatism 2013 criteria for classification of systemic
sclerosis (adapted from van den Hoogen et al.)118
Item Subitems Score†
Skin thickening of the fingers





Skin thickening of the fingers Puffy fingers
Sclerodactyly (distal to MCP
but proximal to PIP)
2
4
Fingertip lesions Digital tip ulcers




Abnormal nail fold capillaries – 2













†Do not add up the scores for subitems, count the highest score that applies
for each item. A total score ≥9 indicates systemic sclerosis (SSc).
‡Any of the antibodies listed as subitems.
MCP, metacarpophalangeal joints; PIP, proximal interphalangeal joints.
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The annual workup should include a thorough clinical investiga-
tion including the mRSS and the following diagnostic measures:
lung function test with body plethysmography including DLCO,
blood pressure, electrocardiography, echocardiography, erythro-
cyte sedimentation rate/C-reactive protein, complete blood
count, clinical chemistry (liver function, creatinine, urea) and
urinary protein.
Differential diagnoses
LS, scleromyxedema, nephrogenic systemic fibrosis, scleredema
and SSc overlap syndromes should be taken into consideration.
To distinguish primary from secondary Raynaud’s phenomenon,
nail fold capillaroscopy and the analysis of autoantibodies are
required. Contributory causes such as vasculitis, thromboangiitis
or arteriosclerotic vascular disease should be excluded (e.g. by
Allen test or fist closure test). Lesions due to calcinosis cutis
should be distinguished from superficial ulceration, yet they are
a possible risk factor for digital ulcers. The histological and
ultrastructural type of myositis can be determined by muscle
biopsy.
Treatment
In order to tailor treatment to the individual patient, it is impor-
tant to determine disease subset, organ involvement and disease
activity. In recent years, the organ-based approach has brought
forward significant pharmacologic advancements, changing
remarkably the prognosis and life quality of patient subgroups.
The present guideline has been prepared bearing in mind that
healthcare systems differ considerably between countries in Eur-
ope. The recommendations, as presented here, may be
influenced, among others, by hospitalization rules, the availabil-
ity of outpatient facilities, and financial reimbursement of speci-
fic procedures and therapies. Many of the recommendations
given below are described in more detail in the ‘Consensus best
practice recommendations for scleroderma’ developed by UK
Scleroderma Study Group.121
Therapy for skin involvement Treatment of Raynaud’s phe-
nomenon. Avoidance of cold exposure is paramount. Heated
gloves, shoes and pockets are usual measures. Furthermore,
paraffin baths, heated seed pillows, therapy balls and physical
therapy are recommended.122 Smoking should be stopped. Beta-
blocker treatment should be substituted, if feasible.
These lifestyle measures should be supported by pharmaco-
logic therapy. First-line therapy consists of calcium antagonists
such as nifedipine or amlodipine. Large meta-analyses revealed
that calcium antagonists reduce the severity and frequency of
Raynaud’s attacks.123 The dosage should be increased carefully.
Recent controlled studies indicated that phosphodiesterase-5
(PDE-5) inhibitors (i.e. sildenafil, vardenafil) may also be effec-
tive in the treatment of Raynaud’s phenomenon by reducing the
severity and frequency of attacks.124–126 However, these drugs
have not been licensed for this indication. Selective serotonin
reuptake inhibitors, such as fluoxetine, have shown benefit in
some patients.127 Angiotensin converting enzyme (ACE) inhibi-
tors or angiotensin-receptor antagonists may also be consid-
ered.128 Improvement of severe Raynaud’s phenomenon has
been demonstrated following intravenously administered ilo-
prost.129,130 A dosage of 0.5–2 ng/kg/min for 3–6 h on at least
five (up to 14) consecutive days at monthly intervals is generally






Centromere Pulmonary arterial hypertension
Topoisomerase-1 (Scl-70) Digital ulcerations, interstitial
lung disease, skin fibrosis















Fc portion of IgG (rheumatoid
factor)
Arthritis
Mitochondrial antigen M2 Primary biliary cirrhosis
Table 6 Organ-oriented baseline diagnostic workup in systemic
sclerosis
Organ system Diagnostic procedures
General Medical history†, physical examination†, complete
blood count†, clinical chemistry†, CRP/erythrocyte
sedimentation rate†, autoantibody testing (Table 5)
Skin Modified Rodnan skin score†, X-ray in case of
calcinosis cutis
Musculoskeletal Clinical examination, creatine kinase, anti-CCP,
rheumatoid factor; in case of myositis, magnetic
resonance imaging and muscle biopsy
Gastrointestinal Upper gastrointestinal tract endoscopy
Lung High-resolution computed tomography, pulmonary
function with body plethysmography (forced vital
capacity, DLCO/SB)†
Heart Electrocardiography†, echocardiography†
Kidneys Blood pressure† (preferably self-monitoring in high-risk
patients‡), serum creatinine†, urinary protein†
†Examinations are likewise recommended for the annual diagnostic workup.
‡For example, patients positive for RNA polymerase III antibodies in serum.
CRP, C-reactive protein; Anti-CCP, antibodies targeting cyclic citrullinated
peptide; DLCO/SB, diffusing capacity of lung for carbon monoxide per single
breath method.
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recommended.131,132 The most frequent side-effects of iloprost
are headaches, low blood pressure and flushing. To minimize
these side-effects, a slow daily increase of the dosage, depending
on the individual patient’s condition, is necessary.132 Digital
(palmar) sympathectomy (with or without botulinum toxin
injection) may be considered in severe and/or refractory cases
(Table 7).128
Treatment of digital ulceration. Avoidance of cold exposure,
cessation of smoking and the avoidance of beta-blocker treat-
ment are accompanying measures. Infections, especially those
that affect deep adjacent structures, should be treated with
antibiotics in order to prevent osteomyelitis and to avoid
amputation.133,134 If possible, the antibiotic therapy should be
combined with vasodilatory agents to improve perfusion of
the involved area. Sufficient analgesic therapy is recommended
to improve quality of life and to reduce pain-induced vaso-
constriction. Adequate wound care and regular clinical inspec-
tion are mandatory, to prevent infections, gangrene or
necrosis.134 In the case of dry, superficial ulcers, non-occlusive
wound care is recommended. The use of a protective wound
dressing (i.e. alginate) is advised when deep ulcers are present
in order to protect the wound from sources of infection and
to support granulation. Wound care includes thorough
cleaning and disinfection with sodium chloride, antiseptics or
other wound cleansing solutions. Two randomized controlled
trials demonstrated that intravenous iloprost is effective in
healing digital ulcers in SSc.131,132 A recent meta-analysis of
several randomized controlled trials indicated that PDE-5 inhi-
bitors foster the healing of digital ulcers135 and can, therefore,
be recommended for the treatment of active digital ulcers.
Bosentan is a non-selective endothelin receptor antagonist that
demonstrated efficacy in the prevention of digital ulcers in
two randomized and controlled studies (RAPIDS-1 and -
2).136–138 A significant reduction in the number of new ulcers
was shown, particularly in patients with multiple ulcers. Side-
effects of bosentan include possible liver toxicity, teratogenicity
and reduced effectiveness of oral contraceptive pills through
interference with the cytochrome P450 enzyme system.131,135
However, bosentan does not affect the healing of existing digi-
tal ulcers. Digital (palmar) sympathectomy (with or without
botulinum toxin injection) may be considered in severe and/
or refractory cases (Table 7).128
Treatment of skin fibrosis. Therapy for skin sclerosis should be
guided by the phase of the fibrotic process (early vs. late











Cessation of smoking, avoidance/discontinuation of beta-blocker therapy, protection from cold exposure
(heated gloves, shoes and pockets) and from trauma
Paraffin baths, heated seed









Calcium channel blocker Vasodilators, analgesics,
antibiotics for infected ulcers
Mild SF:
Phototherapy‡








PDE-5 inhibitor, SSRI, ACE
inhibitor or angiotensin-receptor
antagonist  ASS or clopidogrel;






























†Treatment algorithm proposed by the authors. References are given in the text.
‡UVA1, PUVA or bath-PUVA; Extracorporeal photopheresis may be used as a second-line or adjuvant treatment in early progressive disease.149
§0.5–2 ng/kg/min over 3–6 h on at least five (up to 14) consecutive days at monthly intervals.
ACE, angiotensin converting enzyme; ASS, acetylsalicylic acid; ECP, extracorporeal photopheresis; MMF, mycophenolate mofetil; MTX, methotrexate; RP,
Raynaud’s phenomenon; SF, skin fibrosis; PDE-5 inhibitor, phosphodiesterase-5 inhibitor (sildenafil, vardenafil); SSRI, serotonin reuptake inhibitor (e.g. fluox-
etine).
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phase), the disease activity and the progression of the fibro-
sis. There is currently no approved treatment for skin fibro-
sis. General measures include skin protection from cold and
trauma, skin care with moisturizing creams, lymph drainage
and active physiotherapy for the prevention of contractures.
These general measures may suffice in mild, non-progressing
forms of fibrosis. Small open controlled trials suggest that
manual lymphatic drainage may improve hand function in
SSc.139 In the early phase with limited or localized skin
involvement, UVA1 or bath-PUVA or oral PUVA should be
considered. Similarly to the successful treatment of LS with
UVA modalities, a number of uncontrolled studies have
indicated a beneficial effect on fibrosis in SSc.140–143 How-
ever, controlled studies are still lacking. Pruritus often
occurs in fibrotic skin and may respond to standard therapy
and phototherapy. However, longer treatment durations may
be needed. Photopheresis (extracorporeal photochemother-
apy) has shown promise in several uncontrolled and con-
trolled studies for skin manifestations of SSc.88,144–148
According to the 2014 European Dermatology Forum guide-
lines on photopheresis,149 photopheresis should be used in
SSc on the basis of its safety profile as a second-line or
adjuvant therapy in mono- or combination treatment of the
skin, but not organ, involvement. It is recommended that it
should be applied in early progressive disease, preferably of
less than 2-year duration. For more details, the reader is
referred to the guideline.149
The best data for systemic therapy of progressive skin fibro-
sis are available for methotrexate. In two randomized, con-
trolled studies it was shown that methotrexate decreased skin
fibrosis in early diffuse SSc. Positive effects on other organs
such as the lung could not be shown.150,151 A dosage of 10–
15 mg per week for 6–12 months is generally recommended,
but higher dosages may be considered. The use of MMF is
recommended by the EULAR Scleroderma Trials and Research
(EUSTAR) study group as a second-line therapy following
methotrexate. The recommended standard dosage varies at
about 1–2 g per day for at least 12 months.131,152 An improve-
ment of skin sclerosis was demonstrated for cyclophosphamide
in the scleroderma lung study.131,153 The use of cyclophos-
phamide is recommended after failure of methotrexate and
MMF due to high rates of side-effects.152 As renewed deterio-
ration of the skin score and lung involvement were observed
during follow-up in the scleroderma lung study, a continua-
tion of immunosuppression with MMF or azathioprine after
cyclophosphamide therapy is recommended by some experts.
An algorithm for the treatment of SSc skin fibrosis is shown
in Table 7.
The systemic use of glucocorticoids, which is considered a
standard therapy for most autoimmune diseases, does not
play a role in the therapy of fibrosis in patients with SSc.131
More importantly, it is well known that glucocorticoids at a
dose of >15 mg are associated with a higher incidence of
renal crisis.117
Treatment of calcinosis cutis. Various therapeutic strategies have
been investigated, but there is currently no evidence of an effec-
tive therapy for calcinosis cutis. Ectopic calcifications, or calci-
nosis that compromise blood circulation or cause other
symptoms, may be either removed surgically or by the use of
carbon dioxide laser. Surgical excision seems to be the best
option after failure of conservative treatment attempts. How-
ever, surgery should only be performed in cases of urgent medi-
cal indication.156–158
Treatment of telangiectasia. Telangiectasia may appear in the
face, the hands (even on the palms) and the mucosa of patients
with SSc.159,160 Laser (i.e. potassium titanyl phosphate or flash-
lamp pulsed dye laser) or intense pulsed light therapy is the
treatment of choice to remove telangiectasias.159,161 Cosmetics
are often used to cover the affected area.
Therapy for musculoskeletal involvement For detailed treat-
ment recommendations, the reader is referred to the section
about systemic sclerosis overlap syndromes.
Therapy for pulmonary involvement Treatment of lung fibro-
sis. Interstitial lung disease in many patients is relatively
mild and has a low rate of progression. However, particu-
larly in patients with progressive diffuse disease, a severe
reduction in forced vital capacity can ensue. Progressive lung
fibrosis is recognized as a major cause of mortality.112 It is
therefore crucial to identify patients at risk for interstitial
lung disease and to identify patients with significant deterio-
ration of lung function, as measured by a reduction in
forced vital capacity (>5% in 6 months or >10% in 1 year)
or DLCO (>15% in 1 year). Patients with interstitial lung
disease should be considered for early treatment, when the
disease is active and the damage is still largely reversible.
Another component of therapy should be adequate treat-
ment of reflux disease, as this may prevent progression of
interstitial lung disease.162 The best available data exist for
cyclophosphamide, which showed a modest, statistically sig-
nificant benefit in a randomized, controlled, double-blinded
trial on both lung and skin fibrosis.153 As the follow-up
data of this trial indicated a renewed progression of fibrosis,
several groups recommend the prolongation of immunosup-
pression after 6 or 12 pulses of cyclophosphamide by the
use of azathioprine or MMF.152 Two randomized controlled
trials and a number of uncontrolled studies have shown that
autologous haematopoietic stem cell transplantation (HSCT)
improves lung function and skin fibrosis compared with
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standard immunosuppressive treatment.154,163 Transplantation
can result in rapid (over months) and sustained improve-
ment of mRSS and forced vital capacity. However, in the
first year, a significantly increased mortality was observed in
the transplantation arm.154 Thus, careful selection of SSc
patients for transplantation is mandatory.
Treatment of pulmonary arterial hypertension. Drugs targeting
different aspects of vascular pathology have become avail-
able in recent years. They have dramatically changed the
therapy of pulmonary arterial hypertension. Diagnosis and
therapy of pulmonary arterial hypertension belong in the
hands of an experienced cardiologist/pulmonologist with
special expertise in right-heart disease. The primary task of
the dermatologist taking care of an SSc patient will be to
initiate regular (i.e. at least annual) echocardiography and
to have a high clinical suspicion for this complication
(refer to the 2015 guidelines of the European Society of
Cardiology).164
Therapy for gastrointestinal involvement Standard treatment
for gastrointestinal reflux disease and the prevention of
oesophageal ulcers and strictures is proton pump inhibitors
(i.e. pantoprazole 40 mg/day). The majority of patients
require maintenance therapy. Second-line options are his-
tamine receptor (H2)-blockers and antacids in addition to
appropriate lifestyle changes.131,165 Telangiectasia and gastric
antral venous ectasia may occur and cause gastrointestinal
bleeding which should be treated by endoscopic coagulation.
Prokinetic dopamine agonists may be used for dysphagia
and reflux (e.g. metoclopramide, octreotide).166 Bacterial
overgrowth and fungal infections (e.g. candida esophagitis)
can be managed by intermittent antimicrobial therapy and
antimycotics.167 Anti-diarrhoeal agents (e.g. loperamide) or
laxatives may be used for the symptomatic management of
diarrhoea or constipation that often alternate as clinical
problems. Parenteral nutrition should be considered for
patients with severe weight loss refractory to enteral supple-
mentation. For a more detailed overview, the reader is
referred to the consensus best practice pathway of the UK
scleroderma study group.115
Therapy for renal involvement Prompt recognition of sclero-
derma renal crisis and initiation of therapy with an ACE inhibi-
tor offers the best opportunity for a good outcome. Other anti-
hypertensive agents may be considered for managing refractory
hypertension in conjunction with ACE inhibitors in scleroderma
renal crisis.
The treatments for organ involvement in systemic sclerosis
are summarized in Table 8.
Clinical course and prognosis
The chronic and unpredictable course of the disease implies
regular at least annual follow-up of patients. Multidisci-
plinary care of SSc patients should aim beyond the treat-
ment of classic organ involvement. Quality of life is
increasingly acknowledged in clinical studies and has to be
addressed. The psychosocial well-being of SSc patients is
often severely affected by the impression of disfigurement
(e.g. from telangiectasia, microstomia and contractures),
and patients should be appropriately counselled. This also
applies to the treatment of chronic pain and depression/
anxiety. It has been shown that pain is an important indi-
cator of sexual dysfunction among women with SSc.168
Similarly, erectile dysfunction in male patients is markedly
underdiagnosed and undertreated.169 Furthermore, involve-
ment of the masticatory organ may be significant and lead
to remarkable deterioration of life quality. Likewise, sicca
syndrome, gingivitis, tooth decay and osteolysis/necrosis all
contribute to a deterioration of oral health-related quality
of life.








Pulmonary arterial hypertension Prostanoids, endothelin receptor
antagonist, phosphodiesterase-5
inhibitor, soluble guanylate cyclase
stimulator (riociguat)
Gastrointestinal tract involvement
Reflux disease Proton pump inhibitors, H2
blockers, antacids
Dysphagia and reflux Prokinetics (metoclopramide,
octreotide)




Diarrhoea or constipation Loperamide or laxatives
Malnutrition Parenteral nutrition
Bleeding from gastrointestinal
telangiectasias or antral venous
ectasias
Endoscopic coagulation
Renal disease, renal crisis ACE inhibitor  additional anti-
hypertensive agents
†Some authors recommend to continue immunosuppression after 6 or 12
pulses of cyclophosphamide by the use of MMF or azathioprine.152
ACE, angiotensin converting enzyme; H2, histamine receptor 2; HSCT,
haematopoietic stem cell transplantation.
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Recommendations
• Diagnosis and care should at least in part be in the hands of
specialists who have daily exposure to the disease and have
access to modern diagnostic procedures and to a laboratory
with expertise in autoimmune serology (Tables 5 and 6).
This applies especially to patients with suspected early SSc.
• In order to provide optimal care, cooperation with differ-
ent subspecialties (e.g. rheumatology, dermatology, gas-
troenterology, pulmonary medicine, cardiology and
nephrology) is necessary due to the nature of the disease,
which affects several organ systems. Multidisciplinary care
for patients with early progressive disease should be pro-
vided in a setting where the outpatient facilities also have
access to physical therapy and hospital beds in order to
ensure timely and appropriate diagnosis and treatment
for patients presenting with exacerbation of their disease.
• Capillaroscopy and SSc-specific antibodies seem to be
good prognostic predictors for the disease.
• At least annual, lifelong, follow-up of patients is recom-
mended due to the chronic nature of the disease. In patients
with progressive disease, corresponding with disease activity,
patients should be followedmore frequently.164
• Particularly in patients with an increased risk for renal cri-
sis (progressive diffuse disease, anti-RNA polymerase III
antibodies), regular control of blood pressure (at least
twice weekly/home monitoring) is recommended. Urinary
protein excretion has been determined in several studies
as a major independent risk factor for mortality.170
• Glucocorticoids in higher doses exceeding 15 mg pred-
nisone equivalents should be avoided due to their long-
term side-effects and association with renal crisis.117
• Modern comprehensive disease management should
also consider the associated physical and psychological
consequences.
Systemic sclerosis overlap syndromes
Epidemiology and pathogenesis
SSc overlap syndrome is a term used to describe a very heteroge-
neous group of patients with features of different connective tissue
diseases, combined with clinical signs of SSc.171–173 Epidemiologic
studies report divergent frequencies (incidence and prevalence rates
have not been reported yet) of overlap subgroups, ranging between
9% and 38% of SSc patients.171,172,174,175 The most common
autoimmune diseases overlapping with SSc are polymyositis or der-
matomyositis (~43% of SSc patients), rheumatoid arthritis (~32%),
Sj€ogren’s syndrome (~17%) and systemic lupus erythematosus
(~8%).174 A recent meta-analysis has revealed that the mean age at
diagnosis of patients with SSc overlap syndromes was
47.6  2.6 years, and that it was found more often in European
patients than in patients from North America.176 The question of
why some patients develop only one connective tissue disease and
other patients have a combination of clinical features of different dis-
eases has not yet been answered. A common or overlapping genetic
susceptibility possibly plays an important role.176,177 Koumakis
et al.177 reported that a gene located in the TNFAIP3 region is asso-
ciated with a higher risk of developing SSc polyautoimmunity.
Diagnostic procedures
Clinical presentation and physical examination Most SSc over-
lap syndromes appear to encompass a subtype of SSc similar to lim-
ited cutaneous SSc, but with more frequent involvement of the
musculoskeletal system than in limited or diffuse cutaneous SSc, and
with an apparently earlier onset of lung fibrosis or heart involve-
ment.174,175 Raynaud’s phenomenon is also a very common fea-
ture.173 Digital ulcerations and calcinosis cutis can also be observed
in patients with SSc overlap syndromes.175,178 The other cutaneous
and extracutaneous features depend on the overlapping connective
tissue disease. Involvement of the gastrointestinal tract is probably
the most common internal organ system involved (approximately
50–60%).114,175 Lung fibrosis, pulmonary arterial hypertension and
myocardial involvement are less frequent than in patients with dif-
fuse SSc, but similarly (pulmonary arterial hypertension) or signifi-
cantly more frequent than in limited forms of SSc.175 The skin- and
organ-oriented diagnostic methods used in patients with SSc are
described in detail in the SSc section.
SSc-myositis overlap syndrome Limited cutaneous SSc
together with symmetrical proximal muscle weakness, muscle
pain and/or muscle atrophy with intact reflexes and sensitivity are
the typical clinical features.171,174,175 Patients may develop myosi-
tis before or simultaneously with SSc, or later in the course of
already established SSc. Some patientsmay show cutaneous symp-
toms of dermatomyositis.171 Serologic tests usually show an eleva-
tion of serum creatine kinase (≥4-fold) and acute phase
parameters in blood (e.g. C-reactive protein and erythrocyte sedi-
mentation rate). An electromyography, MRI and muscle biopsy
will help to identify affected muscles.114,179–181 As these patients
have a higher risk of developing diffuse interstitial myocardial
fibrosis which may lead to systolic and diastolic dysfunctions, car-
diac arrhythmia, paroxysmal tachycardia, incomplete or complete
right-heart blocks or heart insufficiency, regular electrocardio-
grams (or Holter monitoring) and echocardiography are
required.172 The frequency of lung and gastrointestinal involve-
ment varies among studies, ranging between 32.0% and 78.1%.172
SSc-Sj€ogren’s overlap syndrome Patients with SSc-Sj€ogren’s
overlap syndrome show a limited form of skin involvement and
a very low frequency of lung involvement.171 Due to a reduced
glandular function, they suffer from dry mouth (xerostomia)
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and dry eyes (xerophthalmia). In addition, these patients also
typically show anti-Ro and anti-La antibodies, often together
with anti-centromere antibodies. Specific diagnostics include
functional tests for ocular and oral sicca symptoms, together
with a glandular biopsy (to detect lymphocytic infiltration).182
SSc-rheumatoid arthritis overlap syndrome A rheumatologic
examination is essential to identify rheumatoid arthritis. Joint
involvement can be due to dermatogenous contractures or inflamma-
tion. It is recommended to examine the rheumatoid factor and anti-
cyclic citrullinated peptide (CCP) antibodies in the serum of affected
patients. X-ray, ultrasound of affected joints, as well as MRI can be
helpful tools to identify inflammation areas and damage of joints.114
However, it is often very difficult to distinguish between SSc patients
with mild, sero-negative arthralgia and those with the significant
arthritis associated with SSc-rheumatoid arthritis overlap syndrome.
SSc-systemic lupus erythematodes overlap syndrome This
subtype is associated with a higher risk of developing polyserositis,
pancreatitis, avascular bone necrosis, lung involvement, lupus
glomerulonephritis, skin rashes and leukoencephalopathy.171 Crea-
tinine clearance, urine analysis to control proteinuria and haema-
turia as well as regular blood pressure tests are necessary for the
early identification of renal involvement.114,183 It may be necessary
to perform a kidney biopsy to distinguish between renal failures
due to lupus nephritis or scleroderma renal crisis.183,184
SSc-antiphospholipid syndrome Apart from autoantibodies
characteristic for antiphospholipid syndrome (Table 9), this rare
condition may be associated with severe ischaemia, pulmonary
arterial hypertonia, digital loss and thromboembolism.171
SSc-autoimmune hepatitis/primary biliary cirrhosis This rare
subtype is mostly associated with limited cutaneous SSc and often
clinically silent. Anti-mitochondrial antibodies, elevation of chole-
static enzymes as well as hyperglobulinemia are possible.171
SSc-sarcoidosis The very rare SSc-sarcoidosis overlap syn-
drome usually presents with elevated temperature, weight loss
















ANA/ENA (Ro, La, ACA)‡ 
Ophtalmologic/ENT review 
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Limited cutaneous systemic sclerosis and …
Figure 2 Flow chart for diagnostic procedures in patients with different SSc overlap syndromes. *Exclude other reason for creatine
kinase elevation (drugs, toxins, thyroid dysfunction). †Some patients may be negative for rheumatoid factor and/or anti-CCP. ‡Rule out
hepatitis C virus positivity, vasculitis and internal organ manifestation. ANA, antinuclear antibodies; Anti-CCP, anti-cyclic citrullinated
peptide antibodies; ENA, extractable nuclear antigen; ENT, ear, nose, throat; MRI, magnetic resonance imaging; SLE, systemic lupus ery-
thematosus; UNL, upper normal limit.
Table 9 Autoantibodies possibly associated with SSc overlap
syndromes
SSc overlap syndrome Antigens targeted by autoantibodies
MCTD U1-snRNP (specific), found in 75–90% of
MCTD patients185,187
SSc-myositis PM/Scl (specific), Ku†, U1- or U3-snRNP,
Scl-70, Jo1, Ro, RNA polymerase III,
RuvBL1/2188,189
SSc-rheumatoid arthritis Rheumatoid factor (high titres in 60–72%),
CCP (64%), Scl-70, centromere172,174
SSc-Sj€ogren’s syndrome Centromere, Ro, La172,174








†Anti-Ku antibodies recognize a protein required for DNA replication and are
characteristic for patients suffering from muscle involvement and severe
interstitial lung disease.190
‡Rare SSc overlap syndromes.171
SSc, systemic sclerosis; SLE, systemic lupus erythematosus; CCP, cyclic
citrullinated peptide; dsDNA, double-stranded DNA; MCTD, mixed connec-
tive tissue disease; PBC, autoimmune hepatitis/primary biliary cirrhosis.
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and bihilary adenopathy. Lung and lymph node biopsy is neces-
sary to define the condition.171
Mixed connective tissue disease Patients with mixed connective
tissue disease (MCTD) present a range of clinical symptoms usually
found in patients with myositis, systemic lupus erythematodes (SLE),
inflammatory arthritis and SSc. Typical for MCTD are puffy fingers
(50%), polyarthritis (65%), Raynaud’s phenomenon (53%), sclero-
dactyly (35%), muscle involvement (80–90%; elevation of serum cre-
atine kinase levels) and oesophageal involvement.185,186 The
occurrence of high antinuclear antibody titres togetherwith high levels
ofU1-snRNP antibodies helps to differentiateMCTD fromother con-
nective tissue diseases.186 Cardiovascular and lung involvement are
less frequent, but aremajor contributors to poor outcome.185
Treatment
There have been major advances in treating many of the organ-
specific complications of SSc and overlapping diseases (see also
Table 8 in the SSc section).
Agents predominantly used to treat SSc overlap syn-
dromes Systemic glucocorticoids. Systemic glucocorticoids can
be used for musculoskeletal involvement together with other
immunosuppressive agents.172
Methotrexate. Methotrexate is still the treatment of choice in
patients with SSc-myositis and SSc-rheumatoid arthritis overlap
syndromes.191,192
Mycophenolate mofetil. Mycophenolate mofetil (MMF) is a well-
tolerated immunosuppressive agent, which is recommended as
long-term therapy in scleroderma. It has been successfully
applied in several overlap syndromes.
Azathioprine. This immunosuppressive agent is usually well tol-
erated and has been successfully used in patients with MCTD as
well as in patients with SSc-SLE overlap syndrome. However,
compared with MMF, side-effects seem to be more pronounced
and the response to the therapy more limited.
Cyclophosphamide. Cyclophosphamide is often used for lung
involvement in patients with SSc,193 and also in SSc-myositis
overlap syndrome or in SSc-SLE overlap syndrome with lupus
nephritis. Cyclophosphamide should be used for musculoskele-
tal involvement as a second-line immunosuppressive therapy
when other treatments (methotrexate, MMF) have failed or
when they cannot be used due to specific side-effects. As in other
autoimmune diseases, it can be used as intravenous pulse or oral
treatment.
Bioimmunomodulatory agents. Limited information is available
for the use of IVIg, rituximab and anti-tumour necrosis factor
(TNF) agents in the treatment of SSc overlap syndromes.
Therapeutic approaches Figure 3 shows the first- and
advanced-line therapeutic approaches for the most frequent SSc
overlap syndromes.118,171,194–199 In patients with MCTD, the
inflammatory features (elevated temperature, serositis, pleuritis,
myositis and arthritis) usually respond well to systemic gluco-
corticoid treatment, while symptoms, such as sclerotic skin
changes and cardiopulmonary involvement need immunosup-




IVIg + MTX + LDG
Refractory: 
Cyclophosphamide or MMF 
or rituximab
SSc-myositis
Hydroxychloroquine + MTX 
+ LDG
If not effective: Consider 
tocilizumab or rituximab or 
anti-TNF agents
SSc-rheumatoid arthritis*
Topical therapy + 
hydroxychloroquine + LDG









Systemic sclerosis overlap syndromes
Figure 3 Flow chart for therapeutic options for different SSc overlap syndromes. *For detailed information, refer to the respective ACR/
EULAR guidelines. IVIg, intravenous immunoglobulin; LDG, low-dose glucocorticoids; MTX, methotrexate; MMF, mycophenolate mofetil;
SLE, systemic lupus erythematosus; SSc, systemic sclerosis; TNF, tumour necrosis factor.
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are hydroxychloroquine, methotrexate and cyclophosphamide,
depending on the severity of the disease.186
Clinical course and prognosis
The prognosis of SSc overlap syndromes is highly dependent on
the involvement of vital organs, as described above for patients
with exclusive SSc. Balbir-Gurman et al.171 reported that the
overall mortality in their SSc overlap cohort did not differ from
other SSc patients.
Recommendations
• Overlap syndromes of SSc with autoimmune diseases
can be distinguished by certain clinical and laboratory
characteristics.
• It is recommended to follow the diagnosis and treat-
ment guidance in Table 9 and Figures 2 and 3.
• Corticosteroid doses higher than 15 mg prednisone
equivalent per day should not be given in patients with
a higher risk for renal crisis.117
• Methotrexate should not be used in case of alveolitis.
• Bioimmunomodulatory agents such as tocilizumab,
rituximab and anti-TNF agents should be used with
caution in the context of serious infections, tuberculosis
and fibrosis.
• In patients with SSc-Sj€ogren’s overlap syndrome, clini-
cal features such as xerostomia and xerophthalmia can
usually be improved by using mouth rinse, saliva substi-
tutes and artificial teardrops, respectively.
• Patients with SSc-SLE overlap syndrome require addi-
tional UV skin protection.
• As the treatment of lupus nephritis differs from sclero-
derma-associated renal failure (cyclophosphamide vs.
vasoactive treatment with ACE inhibitors and iloprost),
a kidney biopsy may be helpful to distinguish between
these two entities.
• Pulmonary and gastrointestinal complications require
treatment as described in Table 8.
• Patients with MCTD usually respond well to systemic
glucocorticoid and immunosuppressive therapy with
classical agents (e.g. hydroxychloroquine, methotrexate
and cyclophosphamide).186,200
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